Fan Lin1, Zongming Eric Chen, Hanlin L Wang. 1. From the Department of Laboratory Medicine, Geisinger Medical Center, Danville, Pennsylvania (Drs Lin and Chen); and the Department of Pathology, University of California, Los Angeles (Dr Wang).
Abstract
CONTEXT: Immunohistochemistry has become a useful ancillary study in the identification and classification of pancreatic neoplasms. The diagnostic accuracy has been significantly improved because of the continuous discoveries of tumor-associated biomarkers and the development of effective immunohistochemical panels. OBJECTIVES: To identify and classify pancreatic neoplasms by immunohistochemistry. DATA SOURCES: Literature review and authors' research data and personal practice experience were used. CONCLUSIONS: To better guide therapeutic decisions and predict the prognostic outcome, it is crucial to make an accurate diagnosis of a pancreatic neoplasm. Application of appropriate immunohistochemical panels enables pathologists to differentiate pancreaticobiliary adenocarcinomas from reactive conditions and to identify rare types of pancreatic neoplasms. Knowing the utilities and pitfalls of each tumor-associated biomarker is essential to avoiding a potential diagnostic error because an absolutely cancer-specific biomarker does not exist. This article reviews frequently used tumor-associated biomarkers, provides lists of effective immunohistochemical panels, and recommends a diagnostic algorithm as a standard approach to pancreatic neoplasms.
CONTEXT: Immunohistochemistry has become a useful ancillary study in the identification and classification of pancreatic neoplasms. The diagnostic accuracy has been significantly improved because of the continuous discoveries of tumor-associated biomarkers and the development of effective immunohistochemical panels. OBJECTIVES: To identify and classify pancreatic neoplasms by immunohistochemistry. DATA SOURCES: Literature review and authors' research data and personal practice experience were used. CONCLUSIONS: To better guide therapeutic decisions and predict the prognostic outcome, it is crucial to make an accurate diagnosis of a pancreatic neoplasm. Application of appropriate immunohistochemical panels enables pathologists to differentiate pancreaticobiliary adenocarcinomas from reactive conditions and to identify rare types of pancreatic neoplasms. Knowing the utilities and pitfalls of each tumor-associated biomarker is essential to avoiding a potential diagnostic error because an absolutely cancer-specific biomarker does not exist. This article reviews frequently used tumor-associated biomarkers, provides lists of effective immunohistochemical panels, and recommends a diagnostic algorithm as a standard approach to pancreatic neoplasms.
Authors: Anna Hoppmann; Adele P Williams; Aubrey Coleman; Clay Tynes; Grant R Williams; Elizabeth Mroczek-Musulman; Jamie Aye; Kimberly F Whelan; Michael R Clay; Sarangarajan Ranganathan; Elizabeth A Beierle Journal: Pediatr Blood Cancer Date: 2019-11-13 Impact factor: 3.167
Authors: T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica Journal: Curr Probl Surg Date: 2020-06-30 Impact factor: 1.909
Authors: Michelle X Yang; Ryan F Coates; Abiy Ambaye; Juli-Anne Gardner; Richard Zubarick; Yuan Gao; Joan Skelly; James G Liu; Mari Mino-Kenudson Journal: Biomark Res Date: 2018-07-27
Authors: Mona M Mamdouh; Hussein Okasha; Hebat Allah M Shaaban; Nesreen H Hafez; Emad Hamza El-Gemeie Journal: Asian Pac J Cancer Prev Date: 2021-10-01
Authors: F A Vuijk; L D A N de Muynck; L C Franken; O R Busch; J W Wilmink; M G Besselink; B A Bonsing; S S Bhairosingh; P J K Kuppen; J S D Mieog; C F M Sier; A L Vahrmeijer; J Verheij; A Fariňa-Sarasqueta; R J Swijnenburg Journal: Sci Rep Date: 2020-10-01 Impact factor: 4.379